The OPTIMISE Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

342 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-29

Study Completion Date

2029-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale:

The cornea is the most transplanted tissue in the Netherlands, with more than 1,500 procedures performed each year. A minimally invasive technique called Descemet Membrane Endothelial Keratoplasty (DMEK) has become the preferred method in the past decade. The main advantage of DMEK over previous techniques is a low graft rejection rate (1-2% per year). Despite this, rejection prophylaxis after DMEK follows the same high potency regimen as previous techniques in the first year, and patients are burdened with indefinite immunosuppression. The current project, OPTIMISE, aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects.

Corticosteroid eye drops are the mainstay of ocular immunomodulatory therapy. Their main side effect is a steroid-induced increase in intraocular pressure (IOP). It manifests in about one-fourth of patients within the first year after surgery and can lead to irreversible optic nerve damage and vision loss. Patients with IOP elevation require additional medications and hospital visits resulting in reduced quality of life and increased costs. The optimal dosing regimen in the first year after DMEK and whether patients may safely stop steroids after one year remains unknown. As a result, protocols in the Netherlands vary considerably from surgeon to surgeon. Patients are potentially over-treated in the short and long-term, resulting in undue burden for the patient and increased costs. Consequently, the Dutch Ophthalmology Society (NOG) identified the optimal short- and long-term immunosuppressive protocol for corneal transplantation as one of its Top 10 knowledge gaps, underscoring relevance for clinical practice. With this work, the investigators expect to address this knowledge gap to the benefit of our patients and society.

Objective:

The OPTIMISE study aims to establish an evidence-based, cost-effective regimen that effectively prevents rejection and minimizes side effects. The hypothesis of this study is that Fluorometholone 0.1% in the first year and discontinuing medication in the second year is a cost-effective treatment strategy after DMEK.

Study design:

The design of this study is a randomized, controlled multicentre trial with a duration of 24 months.

Study population:

The study population will consist of 342 patients aged 21 years or older undergoing DMEK surgery in one eye.

Intervention:

All patients will receive Descemet's Membrane Endothelial Keratoplasty. Following this procedure, patients will be randomized into the following post-operative regime in two stages:

STEP-I (Year 1):

Control group: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Intervention group: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.

STEP-II (Year 2):

Control Group: Half the patients in each study arm will use FML 0.1% daily. Intervention Group: Half the patients in each study arm will discontinue steroids.

Main study parameters/endpoints:

Primary outcomes:

Step-I: IOP elevation compared to baseline Step-II: Endothelial cell loss (ECL) in the second year

Secondary outcomes are:

* Rejection free graft survival.
* Patient reported outcome measures.
* Incremental cost-effectiveness ratios, including a short term trial-based economic evaluation (TBEE) and a life-long model-based economic evaluation (MBEE)
* Structural outcomes including corneal, central macular and retinal nerve fibre layer thicknesses, and optic nerve head imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)

NCT02020044

Fuchs' Endothelial Corneal Dystrophy Bullous Keratopathy Iridocorneal Endothelial Syndrome +2 more

UNKNOWN NA

Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium

NCT01694914

Corneal Transplantation

COMPLETED PHASE3

A Prospective Study of Femtosecond Laser Intracorneal Lensectomi

NCT01673503

Myopia Astigmatism

COMPLETED PHASE3

Safety and Efficacy of the Transform™ Corneal Allograft for Hyperopia Correction

NCT03671096

Hyperopia

WITHDRAWN NA

Outcome of Two Surgical Methods for IOLImplantation in Eyes With Pseudoexfoliation Syndrome

NCT06053554

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pseudophakic Bullous Keratopathy Fuchs' Endothelial Dystrophy Intraocular Pressure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention STEP I (Year 1 after DMEK)

Group Type EXPERIMENTAL

Fluorometholone 0.1% Oph Susp

Intervention Type DRUG

Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.

Year 2: Half the patients in each study arm will use FML 0.1% daily.

Dexamethasone 0.1% ophthalmic suspension

Intervention Type DRUG

Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Control STEP I (Year 1 after DMEK)

Group Type ACTIVE_COMPARATOR

Dexamethasone 0.1% ophthalmic suspension

Intervention Type DRUG

Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Intervention STEP II (Year 2 after DMEK)

Group Type EXPERIMENTAL

Stop steroids

Intervention Type OTHER

Half the patients in each study arm will discontinue steroids.

Control STEP II (Year 2 after DMEK)

Group Type ACTIVE_COMPARATOR

Fluorometholone 0.1% Oph Susp

Intervention Type DRUG

Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.

Year 2: Half the patients in each study arm will use FML 0.1% daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fluorometholone 0.1% Oph Susp

Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.

Year 2: Half the patients in each study arm will use FML 0.1% daily.

Intervention Type DRUG

Dexamethasone 0.1% ophthalmic suspension

Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.

Intervention Type DRUG

Stop steroids

Half the patients in each study arm will discontinue steroids.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients aged 21 years or older registered on the NOTR as candidates for DMEK corneal transplantation

Exclusion Criteria

* Inability to complete follow up or comply with study procedures
* The participant is vulnerable
* Previous corneal graft in the study eye
* Known sensitivity or contraindication to the ingredients in the study medications
* History of uveitis
* History of any herpes simplex infection
* Human Leukocyte Antigen (HLA) typed allograft
* Pregnancy (current and planned) or lactation
* Use of other local or systemic immunosuppressive drugs

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No